Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections

Clinical Infectious Diseases

Volumn 50, Issue 8, 2010, Pages 1120-1126

  McClaine, Rebecca J ^a   Husted, Thomas L ^a   Hebbeler Clark, Renee S ^b   Solomkin, Joseph S ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFOXITIN; CEFTOBIPROLE; CLINAFLOXACIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; LINEZOLID; MEROPENEM; MOXIFLOXACIN; TELAVANCIN; TIGECYCLINE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW;

ANTI-INFECTIVE AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 77950195322     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651264     Document Type: Article

References (22)

1. US Food and Drug Administration (FDA). Guidance for industry: uncomplicated and complicated skin and skin structure infections-developing antimicrobial drugs for treatment. 21 July 1998. http:// www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory-lnformation/Guidances/ucm071185.pdf. Accessed 1 January 2009.
2. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. In: Chalmers I, Altman DG, eds. Systematic reviews. London, England: BMJ Publishing, 1995: 17-36.
3. Nichols RL, Graham DR, Barriere SL, et al; Synercid Skin and Skin Structure Infection Group. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44(2): 263-273.
4. Talan DA, Summanen PH, Finegold SM. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clin Infect Dis 2000; 31(2): 464-471.
5. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44(12): 3408-3413.
6. Siami G, Christou N, Eiseman I, Tack KJ. Clinafloxacin versus piperadllin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001; 45(2): 525-531.
7. Graham. DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34(11): 1460-1468.
8. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38(12): 1673-1681.
9. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin- clavulanatc. Clin Infect Dis 2004; 38(1): 17-24.
10. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49(6): 2260-2266.
11. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a doubleblind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49(11): 4658-4666.
12. Jaurequi LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41(10): 1407-1415.
13. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9(5): 251-261.
14. Fabian TC, File TM, Embil JM, et al. Meropenem versus imipenemcilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 2005; 6(3): 269-282.
15. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26(5): 357-365.
16. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-1703.
17. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52(1): 1-8.
18. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46(5): 647-655.
19. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-1693.
20. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25): 1887-1892.
21. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46(suppl 5): S368-S377.
22. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41(10): 1373-1406.